Assessment of zero-valent iron-based nanotherapeutics for ferroptosis induction and resensitization strategy in cancer cells

Kuang Jing Huang, Yau Huei Wei, Yen Chi Chiu, Shang Rung Wu, Dar Bin Shieh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Addressing nanomedicine resistance is critical for its ultimate clinical success; despite this, advancing .the therapeutic designs for cancer therapy are rarely discussed in the literature. In this study, we discovered that ferroptosis is the central mechanism governing the therapeutic efficacy and resistance of treatment with zero-valent iron nanoparticles (ZVI NPs). In ZVI-sensitive oral cancer cells, ZVI NPs-induced ferroptosis was characterized by mitochondrial lipid peroxidation and reduced levels of glutathione peroxidases (GPx) in subcellular organelles. However, resistant cells could attenuate ZVI-induced oxidative stress and GPx reduction. They also showed stronger mitochondrial respiration ability, thus resisting ZVI NPs-induced mitochondrial membrane potential loss. Transcriptome comparison and quantitative polymerase chain reaction (qPCR) analysis revealed that ZVI-resistant cancer cells expressed a gene set related to enhanced NADPH supply, higher detoxification capacity of reactive oxygen species, and decreased sensitivity to ferroptosis inducers (FINs). Finally, we discovered that certain FINs were able to sensitize ZVI-resistant cancer cells to become treatable without compromising healthy non-malignant cells. These findings suggest that ferroptosis can serve as a druggable target for anti-cancer nanomedicine and therapeutic resistance modulation using ZVI NPs.

Original languageEnglish
Pages (from-to)1311-1322
Number of pages12
JournalBiomaterials Science
Volume7
Issue number4
DOIs
Publication statusPublished - 2019 Apr

Fingerprint

Medical nanotechnology
Iron
Cells
Glutathione Peroxidase
Nanoparticles
Detoxification
Oxidative stress
Polymerase chain reaction
NADP
Lipids
Reactive Oxygen Species
Genes
Modulation
Membranes
Oxygen
Peroxidases
Glutathione

All Science Journal Classification (ASJC) codes

  • Biomedical Engineering
  • Materials Science(all)

Cite this

@article{5eeeadd884664d1cac7a655edcd99fc3,
title = "Assessment of zero-valent iron-based nanotherapeutics for ferroptosis induction and resensitization strategy in cancer cells",
abstract = "Addressing nanomedicine resistance is critical for its ultimate clinical success; despite this, advancing .the therapeutic designs for cancer therapy are rarely discussed in the literature. In this study, we discovered that ferroptosis is the central mechanism governing the therapeutic efficacy and resistance of treatment with zero-valent iron nanoparticles (ZVI NPs). In ZVI-sensitive oral cancer cells, ZVI NPs-induced ferroptosis was characterized by mitochondrial lipid peroxidation and reduced levels of glutathione peroxidases (GPx) in subcellular organelles. However, resistant cells could attenuate ZVI-induced oxidative stress and GPx reduction. They also showed stronger mitochondrial respiration ability, thus resisting ZVI NPs-induced mitochondrial membrane potential loss. Transcriptome comparison and quantitative polymerase chain reaction (qPCR) analysis revealed that ZVI-resistant cancer cells expressed a gene set related to enhanced NADPH supply, higher detoxification capacity of reactive oxygen species, and decreased sensitivity to ferroptosis inducers (FINs). Finally, we discovered that certain FINs were able to sensitize ZVI-resistant cancer cells to become treatable without compromising healthy non-malignant cells. These findings suggest that ferroptosis can serve as a druggable target for anti-cancer nanomedicine and therapeutic resistance modulation using ZVI NPs.",
author = "Huang, {Kuang Jing} and Wei, {Yau Huei} and Chiu, {Yen Chi} and Wu, {Shang Rung} and Shieh, {Dar Bin}",
year = "2019",
month = "4",
doi = "10.1039/c8bm01525b",
language = "English",
volume = "7",
pages = "1311--1322",
journal = "Biomaterials Science",
issn = "2047-4830",
publisher = "Royal Society of Chemistry",
number = "4",

}

Assessment of zero-valent iron-based nanotherapeutics for ferroptosis induction and resensitization strategy in cancer cells. / Huang, Kuang Jing; Wei, Yau Huei; Chiu, Yen Chi; Wu, Shang Rung; Shieh, Dar Bin.

In: Biomaterials Science, Vol. 7, No. 4, 04.2019, p. 1311-1322.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Assessment of zero-valent iron-based nanotherapeutics for ferroptosis induction and resensitization strategy in cancer cells

AU - Huang, Kuang Jing

AU - Wei, Yau Huei

AU - Chiu, Yen Chi

AU - Wu, Shang Rung

AU - Shieh, Dar Bin

PY - 2019/4

Y1 - 2019/4

N2 - Addressing nanomedicine resistance is critical for its ultimate clinical success; despite this, advancing .the therapeutic designs for cancer therapy are rarely discussed in the literature. In this study, we discovered that ferroptosis is the central mechanism governing the therapeutic efficacy and resistance of treatment with zero-valent iron nanoparticles (ZVI NPs). In ZVI-sensitive oral cancer cells, ZVI NPs-induced ferroptosis was characterized by mitochondrial lipid peroxidation and reduced levels of glutathione peroxidases (GPx) in subcellular organelles. However, resistant cells could attenuate ZVI-induced oxidative stress and GPx reduction. They also showed stronger mitochondrial respiration ability, thus resisting ZVI NPs-induced mitochondrial membrane potential loss. Transcriptome comparison and quantitative polymerase chain reaction (qPCR) analysis revealed that ZVI-resistant cancer cells expressed a gene set related to enhanced NADPH supply, higher detoxification capacity of reactive oxygen species, and decreased sensitivity to ferroptosis inducers (FINs). Finally, we discovered that certain FINs were able to sensitize ZVI-resistant cancer cells to become treatable without compromising healthy non-malignant cells. These findings suggest that ferroptosis can serve as a druggable target for anti-cancer nanomedicine and therapeutic resistance modulation using ZVI NPs.

AB - Addressing nanomedicine resistance is critical for its ultimate clinical success; despite this, advancing .the therapeutic designs for cancer therapy are rarely discussed in the literature. In this study, we discovered that ferroptosis is the central mechanism governing the therapeutic efficacy and resistance of treatment with zero-valent iron nanoparticles (ZVI NPs). In ZVI-sensitive oral cancer cells, ZVI NPs-induced ferroptosis was characterized by mitochondrial lipid peroxidation and reduced levels of glutathione peroxidases (GPx) in subcellular organelles. However, resistant cells could attenuate ZVI-induced oxidative stress and GPx reduction. They also showed stronger mitochondrial respiration ability, thus resisting ZVI NPs-induced mitochondrial membrane potential loss. Transcriptome comparison and quantitative polymerase chain reaction (qPCR) analysis revealed that ZVI-resistant cancer cells expressed a gene set related to enhanced NADPH supply, higher detoxification capacity of reactive oxygen species, and decreased sensitivity to ferroptosis inducers (FINs). Finally, we discovered that certain FINs were able to sensitize ZVI-resistant cancer cells to become treatable without compromising healthy non-malignant cells. These findings suggest that ferroptosis can serve as a druggable target for anti-cancer nanomedicine and therapeutic resistance modulation using ZVI NPs.

UR - http://www.scopus.com/inward/record.url?scp=85063496325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063496325&partnerID=8YFLogxK

U2 - 10.1039/c8bm01525b

DO - 10.1039/c8bm01525b

M3 - Article

C2 - 30734774

AN - SCOPUS:85063496325

VL - 7

SP - 1311

EP - 1322

JO - Biomaterials Science

JF - Biomaterials Science

SN - 2047-4830

IS - 4

ER -